Signal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 24, 2013, Pages 9806-9811

  Ferguson, Bradley S ^a   Harrison, Brooke C ^b   Jeong, Mark Y ^a   Reid, Brian G ^a   Wempe, Michael F ^a,c   Wagner, Florence F ^d   Holson, Edward B ^d   McKinsey, Timothy A ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

Cardiac remodeling; Gene transcription; Lysine acetylation

Indexed keywords

DUAL SPECIFICITY PHOSPHATASE; DUAL SPECIFICITY PHOSPHATASE 5; HISTONE DEACETYLASE 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOSOL; ENZYME ACTIVITY; GENE EXPRESSION; GENE REPRESSION; HEART HYPERTROPHY; HEART MUSCLE CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

CARDIAC REMODELING; GENE TRANSCRIPTION; LYSINE ACETYLATION;

ANIMALS; ANIMALS, NEWBORN; BENZAMIDES; CARDIOMEGALY; CELL NUCLEUS; CELLS, CULTURED; DUAL-SPECIFICITY PHOSPHATASES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; IMMUNOBLOTTING; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCYTES, CARDIAC; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84878991183     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1301509110     Document Type: Article

References (48)

1. Roger VL, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2012) Heart disease and stroke statistics - 2012 update: A report from the American Heart Association. Circulation 125(1):e2-e220.
2. Lloyd-Jones D, et al.; WRITING GROUP MEMBERS; American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2010) Heart disease and stroke statistics - 2010 update: A report from the American Heart Association. Circulation 121(7):e46-e215.
3. Devereux RB, et al. (2004) Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 292(19):2350-2356. (Pubitemid 39491919)
4. Gardin JM, Lauer MS (2004) Left ventricular hypertrophy: The next treatable, silent killer? JAMA 292(19):2396-2398. (Pubitemid 39491925)
5. Frey N, Katus HA, Olson EN, Hill JA (2004) Hypertrophy of the heart: A new therapeutic target? Circulation 109(13):1580-1589. (Pubitemid 38451712)
6. Casale PN, et al. (1986) Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 105(2):173-178. (Pubitemid 16039288)
7. Haider AW, Larson MG, Benjamin EJ, Levy D (1998) Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 32(5):1454-1459. (Pubitemid 28522409)
8. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH (1991) Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114(5):345-352.
9. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP (1990) Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322(22):1561-1566. (Pubitemid 20176696)
10. McKinsey TA, Kass DA (2007) Small-molecule therapies for cardiac hypertrophy: Moving beneath the cell surface. Nat Rev Drug Discov 6(8):617-635. (Pubitemid 47207749)
11. Sciarretta S, Sadoshima J (2010) New insights into the molecular phenotype of eccentric hypertrophy. J Mol Cell Cardiol 49(2):153-156.
12. Wettschureck N, et al. (2001) Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes. Nat Med 7(11):1236-1240. (Pubitemid 33063779)
13. Molkentin JD, et al. (1998) A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93(2):215-228. (Pubitemid 28180855)
14. Mishra S, et al. (2010) Cardiac hypertrophy and heart failure development through Gq and CaM kinase II signaling. J Cardiovasc Pharmacol 56(6):598-603.
15. Harrison BC, et al. (2006) Regulation of cardiac stress signaling by protein kinase d1. Mol Cell Biol 26(10):3875-3888. (Pubitemid 43726404)
16. Liu Q, Molkentin JD (2011) Protein kinase Cα as a heart failure therapeutic target. J Mol Cell Cardiol 51(4):474-478.
17. Vega RB, et al. (2004) Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol 24(19):8374-8385. (Pubitemid 39245060)
18. Kehat I, Molkentin JD (2010) Extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy. Ann N Y Acad Sci 1188:96-102.
19. Lorenz K, Schmitt JP, Vidal M, Lohse MJ (2009) Cardiac hypertrophy: Targeting Raf/MEK/ERK1/2-signaling. Int J Biochem Cell Biol 41(12):2351-2355.
20. Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325(5942):834-840.
21. Lundby A, et al. (2012) Proteomic analysis of lysine acetylation sites in rat tissues reveals organ specificity and subcellular patterns. Cell Rep 2(2):419-431.
22. Gregoretti IV, Lee YM, Goodson HV (2004) Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis. J Mol Biol 338(1):17-31. (Pubitemid 38429783)
23. Bush EW, McKinsey TA (2010) Protein acetylation in the cardiorenal axis: The promise of histone deacetylase inhibitors. Circ Res 106(2):272-284.
24. McKinsey TA (2011) Isoform-selective HDAC inhibitors: Closing in on translational medicine for the heart. J Mol Cell Cardiol 51(4):491-496.
25. Fournel M, et al. (2008) MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 7(4):759-768. (Pubitemid 351551029)
26. Tessier P, et al. (2009) Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett 19(19):5684-5688.
27. Butler KV, et al. (2010) Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc 132(31):10842-10846.
28. Methot JL, et al. (2008) Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorg Med Chem Lett 18(3):973 - 978.
29. Moradei OM, et al. (2007) Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem 50(23):5543-5546. (Pubitemid 350106005)
30. Mandl M, Slack DN, Keyse SM (2005) Specific inactivation and nuclear anchoring of extracellular signal-regulated kinase 2 by the inducible dual-specificity protein phosphatase DUSP5. Mol Cell Biol 25(5):1830-1845. (Pubitemid 40280148)
31. Bueno OF, et al. (2000) The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 19(23):6341-6350.
32. Kehat I, et al. (2011) Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth. Circ Res 108(2):176-183.
33. Purcell NH, et al. (2007) Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci USA 104(35):14074-14079. (Pubitemid 350003337)
34. Pandit B, et al. (2007) Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 39(8):1007-1012. (Pubitemid 47185177)
35. Wu X, et al. (2011) MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. J Clin Invest 121(3):1009-1025.
36. Baba HA, et al. (2003) Dynamic regulation of MEK/Erks and Akt/GSK-3beta in human end-stage heart failure after left ventricular mechanical support: Myocardial mechanotransduction-sensitivity as a possible molecular mechanism. Cardiovasc Res 59(2):390-399. (Pubitemid 37272033)
37. Ebisuya M, Kondoh K, Nishida E (2005) The duration, magnitude and compartmentalization of ERK MAP kinase activity: Mechanisms for providing signaling specificity. J Cell Sci 118(Pt 14):2997-3002. (Pubitemid 41149904)
38. Lorenz K, Schmitt JP, Schmitteckert EM, Lohse MJ (2009) A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy. Nat Med 15(1):75-83.
39. Vidal M, Wieland T, Lohse MJ, Lorenz K (2012) β-Adrenergic receptor stimulation causes cardiac hypertrophy via a Gβγ/Erk-dependent pathway. Cardiovasc Res 96(2):255-264.
40. Caunt CJ, Keyse SM (2013) Dual-specificity MAP kinase phosphatases (MKPs): Shaping the outcome of MAP kinase signalling. FEBS J 280(2):489-504.
41. Dickinson RJ, Keyse SM (2006) Diverse physiological functions for dual-specificity MAP kinase phosphatases. J Cell Sci 119(Pt 22):4607-4615. (Pubitemid 44964257)
42. Bueno OF, et al. (2001) The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo. Circ Res 88(1):88-96. (Pubitemid 32064088)
43. Auger-Messier M et al. (2012) Unrestrained p38 MAPK activation in Dusp1/4 double null mice induces cardiomyopathy. Circ Res 112(1):48-56.
44. Maillet M, et al. (2008) DUSP6 (MKP3) null mice show enhanced ERK1/2 phosphorylation at baseline and increased myocyte proliferation in the heart affecting disease susceptibility. J Biol Chem 283(45):31246-31255.
45. Barter MJ, et al. (2010) HDAC-mediated control of ERK- and PI3K-dependent TGF-β-induced extracellular matrix-regulating genes. Matrix Biol 29(7):602-612.
46. Cao DJ, et al. (2011) Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proc Natl Acad Sci USA 108(10):4123-4128.
47. Glenn DJ, Wang F, Chen S, Nishimoto M, Gardner DG (2009) Endothelin-stimulated human B-type natriuretic peptide gene expression is mediated by Yin Yang 1 in association with histone deacetylase 2. Hypertension 53(3):549-555.
48. Chandrasekaran S, et al. (2009) Histone deacetylases facilitate sodium/calcium exchanger up-regulation in adult cardiomyocytes. FASEB J 23(11):3851-3864.